ARF is a tumour suppressor which plays a critical role in p53-dependent or -independent cell growth control. Several studies have recently provided evidence that p14 ARF can also interfere either directly or indirectly with some components of the RB signalling pathway to mediate its antiproliferative activity. The aim of this study was to explore the existence of direct relationships between p14 ARF and RB proteins. We show that p14 ARF promotes the accumulation of a hypoacetylated RB protein, when it is upregulated in a model of stable-inducible clones or physiologically induced following cell exposure to cytotoxic agents. Looking for the mechanisms involved in this process, we demonstrate that the histone acetyl transferase Tip60 directly interacts with RB and stimulates its degradation by the proteasome through acetylation of its C-terminus. Furthermore, and consistent with p14 ARF -induced RB accumulation, we provide evidence that p14 ARF prevents Tip60-mediated RB acetylation, therefore precluding its proteasomal degradation. Overall, our results identify a novel mechanism by which p14 ARF controls the RB pathway to trigger its antiproliferative function.
Introduction
The protein product of the retinoblastoma gene, RB, is a nuclear phosphoprotein that displays multiple biological functions. Through its interaction with the E2F family of transcription factors, RB represses genes that are required for DNA synthesis and arrests cells during the G 1 phase of the cell cycle. Progression of a cell through G 1 and S phases requires inactivation of RB by phosphorylation, which is carried out by cyclin-dependent kinases complexed with their cyclin partners (Sherr and Roberts, 1999) . Furthermore, RB also regulates cell death and studies in mice indicate its direct role in inhibiting apoptosis (Chau and Wang, 2003) . Accordingly, RB is an important substrate of caspase and RB degradation contributes to the induction of apoptosis (Tan and Wang, 1998) . Finally, in vitro tissue culture models support the notion that RB possesses a unique role in mediating differentiation of many tissues and cell types. This is best demonstrated by the requirement for RB during skeletal myogenesis (Lipinski and Jacks, 1999) . Beside regulation by phosphorylation, RB function is also controlled by acetylation (Chan et al., 2001) . In this settings, it was recently demonstrated that RB acetylation by the co-factors p300/CBP and P/CAF is required for the establishment of permanent cell cycle withdrawal and expression of late differentiation (Nguyen et al., 2004) . The histone acetyltransferases (HATs) are divided into five families among which are the p300/CBP HATs and the MYST-related HATs (Carrozza et al., 2003) . The Tip60 protein is a member of the MYST family of HATs. Recent data demonstrate that Tip60 is a key component in the antiproliferative cellular response. Indeed, Tip60 is required for p19 ARF / p53-mediated proliferation arrest and plays a critical role in genotoxic signalling networks (Berns et al., 2004) . p14 ARF is a tumour suppressor gene encoded by the unusual INK4a/p14 ARF locus, which is frequently inactivated in tumours (Sherr, 1998) . It is now clear that the p14 ARF protein (p19 ARF in mouse) exerts its tumour suppressor activity through multiple p53-dependent and -independent pathways. Furthermore, some studies have also pointed out the critical role of the RB signalling pathway in the growth suppressive function of p14 ARF . One important transcriptional target of p53 is the p21 CIP1/WAF1 cyclin-dependent kinase inhibitor which accumulates upon p14 ARF expression and blocks the phosphorylation of the RB protein, thereby causing a G 1 arrest (Sherr and Roberts, 1999) . The E2F transcription factor can activate p14 ARF gene expression and initiate a p53-dependent response (Bates et al., 1998) . Furthermore, we and others have demonstrated that p14 ARF associates with E2Fs and its DP1 regulatory partner and regulates their localization and degradation leading to an inactive E2F1 protein (Eymin et al., 2001; Martelli et al., 2001; Datta et al., 2002; Mason et al., 2002) . Collectively, these observations demonstrate that p14 ARF interferes in a direct or indirect manner with some effectors of the RB signalling pathway to control cell growth. The importance of such relationships is underlined by the fact that in a genetic study in mice, p14 ARF has been reported to functionally activate both the p53 and the RB pathways (Carnero et al., 2000) .
In the present study, we attempted to investigate the functional impact of p14 ARF on RB by exploring the existence of direct relationships between both proteins. Our results show that p14 ARF stabilizes RB by preventing its Tip60-mediated acetylation and further degradation by the proteasome. In addition, we present data indicating that RB accumulates in a p14 ARF -dependent manner following DNA injuries.
Results

P14
ARF induces accumulation of hypoacetylated RB In an effort to explore the putative relationships linking p14 ARF and RB, we analysed the consequences of p14 ARF expression on the RB status. To do this, we used a model of stable p14ARF-inducible clones derived from the p53-deficient H358 human lung adenocarcinoma cell line (Eymin et al., 2003) . In these cells, p14 ARF expression is induced upon 1 mg/ml doxycyclin treatment. We reproducibly noticed that the level of the endogenous RB protein was upregulated after 48 h of p14 ARF expression ( Figure 1a) . To confirm the effects of p14 ARF , similar experiments were performed in H1299 and A549 cells transiently transfected for 48 h with a p14 ARF encoding vector. Again, accumulation of RB protein was detected in response to p14 ARF ( Figure 1b ). Of note, we never observed mobility shift of the endogenous RB protein, suggesting that p14 ARF does not apparently modulate the phosphorylation status of RB in these cells. As acetylation was previously reported to affect RB steady-state level (Nguyen et al., 2004) , we analysed in p14 ARF -inducible cells the acetylation status of endogenous RB using immunoprecipitation experiments followed by immunoblotting with anti-acetylated lysine antibody. As shown in Figure 1c , the induction of p14 ARF expression resulted in a reproducible decrease in the acetylated RB expression level. Collectively, these data demonstrate that p14
ARF induces the accumulation of a hypoacetylated RB protein.
Tip60 HAT interacts with RB and acetylates its carboxyterminus During the course of this study, we obtained data demonstrating that the Tip60 protein plays a critical role in the tumor suppressive function of p14 ARF (Eymin et al., submitted) . As Tip60 displays an intrinsic HAT activity, we extrapolated from our results that Tip60 could regulate the acetylation of RB in response to p14 ARF . To test whether RB was a target of Tip60, we initially investigated the possibility of a physical interaction between both proteins. A GST pull-down assay was carried out where 35 S-labelled in vitrotranslated Tip60 was mixed with beads harbouring either bacterially expressed glutathione S-transferase (GST)LP fusion protein containing the large pocket (LP) of RB or GST as a control. In this direct binding assay, Tip60 protein was efficiently retained on the GST-LP beads but not on GST indicating that Rb and Tip60 interact physically in vitro (Figure 2a ). To confirm these results in living cells, we transfected SAOS2 (RBÀ) cells with expression vectors for RB and/or HA-tagged Tip60. At 48 h post-transfection, whole-cell extracts were subjected to immunoprecipitation with an anti-RB antibody followed by immunoblotting with anti-HA antibody. Surprisingly, when Tip60 was co-transfected, we observed a strong downregulation of RB steady-state level as detected by Western blotting (Figure 2b , compare lanes 2 and 3). Nevertheless, a Tip60/RB complex was detected in these conditions (Figure 2b , lane 7). Finally, we intended to demonstrate that endogenous Tip60 and RB could also form complex. We immunoprecipitated endogenous RB from H1299 nuclear extracts and tested for the presence of coimmunoprecipitated Tip60 by Western blotting using an anti-Tip60 antibody. As shown in Figure 2c , immunodetection of a Tip60 protein was clearly observed in RB immunoprecipitates indicating that both proteins physiologically interact 'in vivo'. This interaction was specific since it was not observed with a control mouse IgG (Ctl). Taken together, the results identify Tip60 as a new direct RB-binding partner. ARF regulates RB acetylation C Leduc et al Then, we investigated the ability of Tip60 to catalyse RB acetylation. An 'in vitro' acetyltransferase assay was set up where a GST-LP fusion protein was used as a putative substrate for the HAT domain of Tip60 (HisTip 212À513 ) ( Figure 3a ) in the presence of C 14 -Acetyl-CoA. As detected by autoradiography, recombinant Tip60 was able to acetylate efficiently the large pocket of RB (Figure 3b lane 2) . In similar conditions, we observed that the C pocket of RB was acetylated by Tip60, whereas the A/B pocket domain was apparently not ( Figure 3b lanes 4 and 3, respectively). These data revealed that Tip60 acetylates the carboxy terminal part of the RB protein. To analyse whether RB was acetylated by Tip60 in vivo, we used siRNA raised against Tip60. The endogenous RB protein was precipitated with an anti-RB antibody in H358 cells depleted or not for the Tip60 protein, and its acetylated status was analysed by Western blotting with an antiacetylated lysine antibody. We observed that RB was less recognized by the anti-acetylated lysine antibody in Tip60-deprived cells as compared to control cells, although it was efficiently immunoprecipitated ( Figure 3c ). These results indicated that Tip60 regulates RB acetylation in living cells. Furthermore, they also demonstrated that the acetylation of RB detected by the anti-acetyl lysine antibody in Figure 1c is because of Tip60. Interestingly, we noticed an increase of RB expression when Tip60 was knock down in agreement with our previous results showing a strong downregulation of RB upon Tip60 expression (Figure 2b ).
Tip60-mediated acetylation contributes to RB degradation by the proteasome As our data indicated that Tip60 regulates RB expression level (Figures 2b and 3c ), we wanted to further explore the mechanisms involved in this process. RB is subjected to proteasome-mediated proteolysis (Uchida et al., 2005) . We therefore tested whether Tip60 could target RB for proteasomal degradation. SAOS2 cells . Whole-cell extracts were subjected to immunoprecipitation with anti-RB antibody followed by immunoblotting with anti-acetyl antibody (Ac-K). The Ac-K blot was stripped and re-probed with anti-RB antibody to confirm the presence of an overlapping RB band. Extracts of H358 cells transfected with siRNA were also loaded directly to see downregulation of Tip60 expression (input). Note the accumulation of RB in Tip60-depleted cells.
p14
ARF regulates RB acetylation C Leduc et al were co-transfected with pcDNA3.1-RB and pcDNA3.1-SKP2 as a control in the presence or absence of pcDNA3.1-HA-Tip60 and treated or not by the proteasome inhibitors MG132 or MG115. According to Western blotting, treating cells with either inhibitor prevented the capacity of Tip60 to downregulate RB protein expression, whereas the SKP2 expression level did not vary in the same conditions (Figure 4a ). These results indicated that Tip60 promotes RB degradation through the proteasome pathway. To strengthen the notion that Tip60 affects the stability of the RB protein, we used cycloheximide (CX), a widely used inhibitor of translation. H1299 cells were transfected with RB expression vector in the presence or absence of HATip60, and the amount of exogenous RB remaining after different periods of time of CX treatment was studied. The data showed that RB half-life decreased significantly in the presence of Tip60, whereas the expression of a control Skp2 protein was not affected in the same conditions ( Figure 4b ). Of note, we noticed that Tip60 expression slightly decreased following 6 h of CX treatment consistent with a previous report demonstrating Tip60 proteasomal degradation (Legube et al., 2002) .
Having demonstrated that Tip60 acetylates RB and also induces its proteasomal degradation, we therefore hypothesized that both phenomenoms could be linked. To test this hypothesis, we used a mutated Tip60 (Tip60 G380 ) containing a mutation severely impairing its HAT activity (Lemercier et al., 2003) . RB was coexpressed in SAOS2 cells with either HA-Tip60 or HATip60 G380 and Western blot experiments were performed. Co-expression of a SKP2 protein was used as a control. Figure 4c shows that the level of RB was not significantly altered when the mutant HA-Tip60 G380 (which is expressed at levels equal to wild type) was co-transfected (compare lanes 2 and 3) supporting the fact that Tip60 HAT activity is required for the decrease of RB. Furthermore, this was not caused by defects in RB binding, as HA-Tip60 G380 was still able to interact with RB in a GST pull-down assay ( Supplementary  Figure 1) . Importantly another RB acetylase, the p300 HAT (Chan et al., 2001) , did not decrease the levels of RB but rather induced an overall upregulation of RB expression (Figure 4c lane 4) in agreement with previous data (Nguyen et al., 2004) . Such opposite effects suggested that the lysine residues acetylated by Tip60 and p300 (or at least some of them) might be distinct. Lysine residues 873/874 have been reported as important sites for acetylation of RB by p300 (Chan et al., 2001) and also P/CAF (Nguyen et al., 2004) . Thus, we reasoned that a RB.RR mutant in which the lysine residues 873/874 are mutated to arginine might be unable to be acetylated by Tip60. This mutant has been previously reported to display a reduced capacity for p300-and P/CAF-mediated acetylation (Chan et al., 2001; Nguyen et al., 2004) . SAOS2 cells were transfected with either HA-Tip60 or p300 expression vectors along G380 with impaired HAT domain or p300. Western blotting was performed using the indicated antibodies. (d) H1299 cells were transfected with RB or mutant RB/RR in the presence or absence of HA-Tip60 or p300. Whole-cell extracts were subjected to immunoprecipitation with anti-RB antibody followed by immunoblotting with anti-acetyl antibody (Ac-K). RB immunoblotting was performed on the IP blot after stripping. The input represents 10% of total protein extracts and allows the detection of HA-Tip60 and p300 HATs.
ARF regulates RB acetylation C Leduc et al with RB or RB-RR and incubated with MG132 to prevent downregulation of RB by Tip60. The exogenous RB or RB-RR was then immunoprecipitated with anti-RB antibody and subjected to a western blot analysis with the anti-acetyl antibody. Whereas the RB.RR mutant displayed a reduced capacity for p300-mediated acetylation (Figure 4d compare lanes 4 and 5), we observed that Tip60 acetylated RB.RR as efficiently as the wild-type RB protein (Figure 4d compare lanes 2 and 3). Of note, the RB.RR expression was also downregulated upon Tip60 expression (data not shown). These data therefore indicated that the lysine residues targeted by Tip60 are distinct from those acetylated by p300 and P/CAF. p14 ARF prevents Tip60-mediated RB acetylation and degradation by the proteasome Our results demonstrated that Tip60 contributes to the proteasomal degradation of the RB protein through acetylation of its C-terminus moı¨ety. Therefore, we wondered whether p14 ARF could stabilize RB by affecting its acetylation by Tip60. To show that p14 ARF regulates Tip60-mediated RB acetylation, we performed an 'in vitro' HAT assay similar to that reported in Figure 3 and tested the consequences of the addition of a GST-p14 ARF fusion protein on the capacity of Tip60 to acetylate RB. This assay revealed that p14 ARF inhibited in a dose-dependent manner the acetylation of RB mediated by Tip60 (Figure 5a ). According to the results described in Figure 4 , inhibition of RB acetylation by p14 ARF would therefore induce RB accumulation. To confirm this, we tested whether p14 ARF modulates the stability of the RB protein in the presence of Tip60.
H1299 cells were co-transfected with RB, HA-Tip60 and SKP2 expression vectors and the amount of exogenous RB remaining after various durations of CX treatment was analysed in the presence or absence of p14 ARF . As expected, expression of p14 ARF was associated with a strong decrease in Tip60-mediated RB decay (Figure 5b) . Overall, these data showed that p14 ARF promotes RB accumulation by inhibiting its Tip60-dependent acetylation.
ARF is required for RB accumulation in response to melphalan During the course of this study, we also obtained evidence that p14 ARF and Tip60 played interrelated roles in the cellular response to alkylating agents (Eymin et al., submitted) . We therefore wondered whether RB was regulated in this context. To test this, H358 cells were cultured for 24 h in the presence or absence of melphalan (10 mM) and analysed for RB expression and acetylation status as described above. As expected from our previous data, treating cells with melphalan upregulated p14 ARF expression (Figure 6a and data not shown). Furthermore, we observed that the levels of RB protein paralleled those of p14 ARF , showing a significant accumulation in response to melphalan (Figure 6a ). In contrast, the fraction of acetylated RB in the RB immunoprecipitates decreased when the cells were incubated with melphalan indicating that hypoacetylated RB accumulates in response to this genotoxic agent (Figure 6b ). Considering the important role of p14 ARF in the positive regulation of RB steady-state level through inhibition of Tip60-dependent acetylation (see Figure 5 ), we hypothesized that p14 ARF could participate ARF is indeed necessary for RB accumulation following DNA damage, the protein was downregulated using appropriate siRNA. RB level was then analysed by Western blotting in cells treated nor not with melphalan. In agreement with p14 ARF being a positive regulator of RB expression (Figures 1a and b and 5b) , we observed that p14 ARF depletion strongly reduced RB expression level in untreated cells (Figure 6c, compare lanes 1 and 2) . Furthermore, we also showed that the upregulation of RB expression level observed in the presence of melphalan was completely abolished when p14 ARF was knockdown (Figure 6c, compare lanes 3 and 4) . Taken together, these results demonstrate that RB is stabilized by physiological induction of p14 ARF in response to DNA injuries and support the role of Tip60 in these settings.
Discussion
A large body of data demonstrates that p14 ARF displays its tumor suppressor activity by controlling various signalling pathways that impinge on gene expression or cell growth control. Accordingly, the number of identified cellular partners of p14 ARF is increasing daily. In this study, we identify the RB protein as a key target of p14 ARF . Acetylation control of the RB protein is a recent notion. Indeed, the identification of acetylation as a new type of post-translational modification of RB was reported few years ago by Chan et al. (2001) , who demonstrated the capacity of the p300/CBP HAT to acetylate RB 'in vitro'. 'In vivo' evidence of RB acetylation was further provided in various differentiation cell culture systems in which the p300-associated factor (P/CAF) was reported to catalyse RB acetylation in cooperation with p300 (Nguyen et al., 2004) . In this study, we identify Tip60 as a new RB acetylase and demonstrate its critical role in controlling RB expression. In most of the cases, protein acetylation plays a direct role in preventing degradation. In this regard, p53 nicely illustrates this phenomenon. As acetylated p53 lysine residues overlap with those that are ubiquitinated, it has been proposed that a major function of p53 acetylation is to promote p53 stability by preventing mdm2-dependent ubiquitination (Ito et al., 2002) . On the other hand, some reports have also described an accelerated protein degradation following lysine acetylation (Caron et al., 2005) . In these cases, lysine acetylation governs protein stability essentially by modulating protein-protein interaction. Here, we show that acetylation by Tip60 promotes RB degradation by the proteasome. Interestingly, RB acetylation was reported to increase mdm2 binding (Nguyen et al., 2004) and mdm2 was recently shown to induce ubiquitin-dependent degradation of RB (Uchida et al., 2005) . Therefore, one might propose that Tip60-mediated RB acetylation enhances mdm2 binding and subsequent RB ubiquitination and degradation by the proteasome. Interestingly, we obtained evidence that the lysine residues acetylated by Tip60 differs from those targeted by p300 and P/CAF, at least for the lysines 873/ 874. As acetylation by p300 and P/CAF was reported to promote RB stabilization (Nguyen et al., 2004) , these results suggest that depending on the acetylase and on the targeted lysine residues, acetylation could differentially affect RB expression level and trigger distinct biological effects. In our cells, this was clearly seen as Tip60 but not p300 expression was found to decrease RB as well as RB.RR levels. In this respect, it is interesting to notice that Tip60 and the co-factors p300 and P/CAF belong to different families of HATs which display diverse cellular functions (Carrozza et al., 2003) .
It is presently well-known that p14 ARF promotes p53 accumulation through mdm2 inhibition, thus triggering a p53-transcriptional program that leads to RB hypophosphorylation and cell cycle arrest (Sherr, 2001) . Here, we show that p14 ARF induces RB accumulation by inhibiting its Tip60-dependent acetylation, identifying a new mechanism by which p14 ARF controls the RB pathway. Furthermore, as RB accumulation is observed in p53-deficient cells, our results suggest that RB could participate to the negative growth control mediated by p14 ARF in the absence of functional p53. Consistently, we have obtained some results showing that p14 ARF is unable to induce a cell cycle arrest in RB-deficient SAOS2 cells and that RB knockdown partially prevents p14 ARF -mediated G 2 arrest in our stable inducible clone (data not shown). These data are reminiscent with a previous study showing that p19
ARF normally functions ARF as indicated before melphalan was added. Whole-cell extracts were subjected to Western blot analysis with the indicated antibodies.
p14
ARF regulates RB acetylation C Leduc et al by regulating both the RB and p53 pathways (Carnero et al., 2000) . In addition, we recently demonstrated that p14 ARF and Tip60 cooperate to induce a p53-independent DNA damage checkpoint in response to alkylating agents (Eymin et al., submitted) . In the present study, we show that RB accumulates in a p14 ARF -dependent manner in cells treated with melphalan supporting the notion that RB may participate to the Tip60-mediated DNA damage response induced by p14 ARF . Collectively, our data therefore suggest that the variations of Rb expression directly contribute to the cell cycle arrest induced by p14
ARF . We had previously demonstrated the strong mutual exclusion between p14 ARF inactivation and aberrant mdm2 overexpression in human lung tumours (Eymin et al., 2002) . It is remarkable that according to our and other results, both of these alterations trigger RB inactivation and consequent G 1 arrest evasion. Strikingly, these mutually exclusive alterations invalidate critical functions of both p53 and RB on the control of tumour growth.
Materials and methods
Vectors pcDNA3.1-RB, pcDNA3.1-SKP2 and pSG5L-RB(873-874RR) were kind gifts from Dr D Trouche, Pr Larsson and Dr McCance, respectively. pcDNA3.1-p14 ARF was previously described (Eymin et al., 2001) . pcDNA3.1-p300 was provided by Dr S Kochbin. pcDNA3-HA-Tagged Tip60, pcDNA3 HA- Tagged Tip60   G380 and production of His-Tip 212À513 were described elsewhere (Lemercier et al., 2003) .
Cell culture, transfection and treatments H1299 and H358 were lung adenocarcinomas and A549 was a squamous cell carcinoma of the lung. All expressed the RB protein and were cultured in RPMI-1640 supplemented with antibiotics and heat-inactivated fetal calf serum (FCS) (10%). A549 expressed a wild-type p53 protein, whereas p53 was mutated or deleted in H1299 and H358 cells, respectively. SAOS2 cells were derived from an osteosarcoma deficient for RB and p53 expression and were cultured in McCoy medium supplemented with antibiotics and heat-inactivated FCS(10%). H358/Tet-On/p14 ARF conditionally expresses p14 ARF upon doxycyclin treatment (1 mg/ml) and was previously generated in the laboratory from the H358 cell line (Eymin et al., 2003) . These cells are cultured in RPMI-1640 in the presence of 10% FCS, hygromycin (200 mg/ml) and geneticin (100 mg/ml). Transfections with mammalian expressing vectors were carried out using Fuge`ne 6 (Roche Diagnostic, Meylan, France) according to the manufacturer's protocol. The amounts of expression vectors were normalized with the corresponding empty vectors. Cells were harvested 24 or 48 h post-transfection.
For siRNA treatment, transfection was carried out using Oligofectamine (Invitrogen, Cergy Pontoise, France) according to the manufacturer's protocol. The sequence designed to target specifically human p14 ARF and Tip60 RNAs were as follow: p14 ARF oligonucleotides duplex was performed for 48 h, then alkylating agents were added for 24 additional hours.
Treatment with melphalan (10 mM) was carried out for 24 h. Proteasome inhibition was achieved by treating cells with either MG132 (3 mM) for 18 h or MG115 (30 mM) for 6 h. For the study of RB acetylation, cells were incubated with TSA (50 ng/ml) for 18 h before lysis. Protein translation inhibition was achieved by treating the cells with 15 mg/ml of CX (Sigma, Saint Quentin Fallavier, France) 24 h post-transfection.
Antibodies
The anti-RB (G3-245) was purchased from Pharmingen, BD Biosciences Le Pont de Claix, France, the anti-HA (Y11) from Boerhinger Manheim, the anti-SKP2 (2B12) from Zymed (In Vitrogen, Cergy Pontoise, France), the anti-acetyl-Lysine from Upstate (Euromedex, Mundosheim, France), the anti-p300 (C20) from Santa Cruz, Tebu-Bio, Le Perray en Yvelines, France, the anti-p14 ARF (Ab-2) from Oncogene Research (Merck Eurolab, Fontenay sous bois, France), and the antiactin (20-33) from Sigma. Anti-Tip60 antibody was kindly provided by B Amati.
Western blot and immunoprecipitation experiments
Whole-cell extracts were obtained by lysing cell pellets in TNE buffer (150 mM NaCl, 50 mM Tris pH 7.4, 0.5% NP40, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA) supplemented with protease inhibitors and DNAse. Protein lysates were sonicated at 300 W and equal amount of proteins were separated by SDS-PAGE. Western blotting was further processed by standard procedures and revealed by chemiluminescence with an ECL detection system (Amersham, Orsay, France).
For immunoprecipitation experiments, cells were lysed in TNE buffer supplemented with protease inhibitors and DNAse. In all, 1-2 mg of total protein extract was immunoprecipitated with the indicated antibodies at 41C overnight and resolved by Western blotting. For the study of RB acetylated status, TSA (100 ng/ml) was added to the lysis buffer. The Ac-K blot was stripped and immunoblotted with anti-RB antibody to confirm the presence of an overlapping band. Co-immunoprecipitation of endogenous proteins was performed on nuclear-enriched cell fraction from H1299 cells, which was lysed in 300 mM NaCl, 50 mM Tris pH 8.0, 0.4% NP-40, 10 mM MgCL 2 , 2.5 mM CaCL 2 supplemented with protease inhibitors and DNAse, diluted in an equal volume of dilution buffer (50 mM Tris pH 8.0, 0.4% NP-40) and treated as described above. Immunoblotting was carried out using anti-Tip60 and anti-RB antibodies.
In vitro acetyltransferase assays Histone acetyltransferase assays were performed using 2 mg of each GST-LP, GST-C and GST-AB proteins, 200 ng of recombinant His-tagged Tip60 212À513 protein and 0.2 mCi of ( 14 C)Acetyl-CoA (50 Ci/mmol, ICN) in HAT buffer (25 mM Tris pH 8.0, 10% glycerol, 100 mM NaCl, 1 mM DTT, 0.2 mM EDTA, 0.2 mM PMSF, 5 mM sodium butyrate) for 30 min at 301C. In some experiments, GST-p14 ARF protein (100-400 ng) was added to the reaction. Seventy percent of the reactions were loaded on a 7% SDS-polyacrylamide gel followed by Coomassie Blue staining to ensure proper loading, and fluorography was performed after incubation of the gel in the Amplify solution (Amersham Biosciences).
GST pull-downs Recombinant GST or GST-LP was produced in Escherichia coli and incubated with 'in vitro' translated 35 S-labelled Tip60 (TNT, Promega, Charbonnie`res les Bains, France) produced p14 ARF regulates RB acetylation C Leduc et al from pcDNA3.1-HA-Tip60 vector using T7 polymerase. GST pull-down was performed in washing buffer for 2 h at room temperature with about 1 mg of GST fusion proteins. Beads were washed three times as described previously (Eymin et al., 2001 ) and analysed by SDS-PAGE followed by fluorography (Amplify; Amersham).
